UNSPSC 51411904: Fenalcomine

This classification denotes a vasodilating agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1TBQ3A47P8. European Medicines Agency schedules Fenalcomine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07536MIG. Fenalcomine generally arises in the molecular formula C20H27NO2.

UNSPSC 51411904 Fenalcomine, a Commodity code, covers pharmaceutical supply to state and local government agencies, particularly emergency medical services and health benefit programs. Recent solicitations show state and local governments buying specific advanced life support medications, generic multi-source pharmaceuticals, and over-the-counter products through formal competitive procurements. The City of Tampa's April 2026 sealed-bid solicitation for Advanced Life Support Medications (four specific drug line items totaling approximately 3,530 units for Tampa Fire Rescue) and the Minnesota Multistate Cooperative Purchasing Alliance's January–March 2026 RFP for generic multi-source pharmaceuticals and OTC products across participating state and local facilities exemplify the scope. Issuing bodies include municipal purchasing departments (city of Tampa), state health agencies (Texas Health and Human Services Commission), and cooperative purchasing vehicles serving multiple jurisdictions (Minnesota MMCAP). The cooperative purchasing channel—MMCAP administering contracts across state and local facilities in Minnesota and Oregon—represents a significant mechanism for pharmaceutical procurement at this tier.

Geographic activity concentrates in the South and Midwest. The City of Tampa in Florida issued the sealed-bid solicitation with a $40,000 estimated contract value, response deadline April 8, 2026, and a one-year term with two optional renewals plus up to three additional 30-day extensions, with a 5 percent bid discount available under the city's Small Local Business Enterprise (SLBE) sheltered market designation. Minnesota MMCAP's RFP (due March 26, 2026) for generic pharmaceuticals requires vendor compliance with cGMP, DSCSA, and FDA requirements, mandates relationships with authorized wholesalers AmerisourceBergen (Cencara), Cardinal Health, and Morris & Dickson, and imposes a 3 percent administrative fee on all purchases with performance penalties of $200–$1,500 per violation. Texas HHS Commission issued a preliminary Request for Information (April 3, 2026) exploring direct-to-manufacturer prescription models outside traditional PBM and GPO channels, signaling a longer-term procurement strategy still in the market-intelligence phase. Vendors should expect Safety Data Sheets (OSHA HCS compliance), comprehensive insurance requirements ($5,000,000 general liability minimums in cooperative contexts), and minimum shelf-life certification across all solicitations.